Akums Drugs has announced the purchase of Oriflame India's manufacturing business for ₹56 crore, adding two production plants to its portfolio. The deal marks the company's entry into the color cosmetics market, moving beyond its primary pharmaceutical contract manufacturing business. The transaction is expected to finalize by August 31, 2026.
Detailed Coverage
Akums Drugs and Pharmaceuticals, primarily known for its contract development and manufacturing organization (CDMO) services, is diversifying its operations into the color cosmetics segment. The company has entered into a definitive agreement to acquire the manufacturing operations of Oriflame India for a total consideration of ₹56 crore. This transaction, expected to conclude by the end of August 2026, involves the transfer of two manufacturing facilities located in Roorkee, Uttarakhand, and Noida, Uttar Pradesh, as well as a leased warehouse.
Expanding Manufacturing Capabilities
The acquisition provides Akums with readymade production capacity for products such as lipsticks, foundations, and eyeliners. The facilities currently utilize European machinery and hold Halal certifications, which the company intends to leverage for both domestic sales and potential export opportunities. By integrating these assets, Akums is attempting to broaden its manufacturing base beyond its traditional pharmaceutical and healthcare focus areas, such as skincare and haircare, into the broader beauty and personal care market.
Strategic Context and Market Position
For Akums, this move represents a shift in its capital allocation strategy, moving from purely medical and healthcare-related contract manufacturing into consumer-facing cosmetics. The company has historically operated as a partner for other brands in the pharmaceutical industry. By moving into color cosmetics, Akums is positioning itself to capture demand from the growing Indian beauty sector. The firm's management has indicated that this acquisition is intended to create synergies with its existing manufacturing business, allowing them to serve a wider client base.
Financial and Operational Considerations
Investors may monitor how this acquisition affects the company’s profit margins in the coming quarters, as integrating new manufacturing units often involves initial setup costs and operational adjustments. Akums operates in a competitive environment where maintaining efficient plant utilization is necessary to protect returns on capital. Unlike pharmaceutical manufacturing, which is subject to stringent drug regulatory approvals, the cosmetics business operates under different regulatory frameworks for personal care products. The success of this expansion will depend on the company's ability to maintain high manufacturing standards while effectively marketing these new capabilities to existing and potential clients. Future updates on the integration process, the transition of existing client contracts from Oriflame, and the ramp-up of capacity utilization at the newly acquired sites will be key areas for stakeholders to watch as the deal reaches its completion date.